Evaluation of the Antitumour and Antiproliferative Effect of Xanthohumol-Loaded PLGA Nanoparticles on Melanoma

Data de publicação:

Autores da FMUP

  • Raquel Ângela Silva Soares Lino

    Autor

Participantes de fora da FMUP

  • Fonseca, M
  • Macedo, AS
  • Lima, SAC
  • Reis, S
  • Fonte, P

Unidades de investigação

Abstract

Cutaneous melanoma is the deadliest type of skin cancer and current treatment is still inadequate, with low patient survival rates. The polyphenol xanthohumol has been shown to inhibit tumourigenesis and metastasization, however its physicochemical properties restrict its application. In this work, we developed PLGA nanoparticles encapsulating xanthohumol and tested its antiproliferative, antitumour, and migration effect on B16F10, malignant cutaneous melanoma, and RAW 264.7, macrophagic, mouse cell lines. PLGA nanoparticles had a size of 312 +/- 41 nm and a PdI of 0.259, while achieving a xanthohumol loading of about 90%. The viability study showed similar cytoxicity between the xanthohumol and xanthohumol-loaded PLGA nanoparticles at 48 h with the IC50 established at 10 mu M. Similar antimigration effects were observed for free and the encapsulated xanthohumol. It was also observed that the M1 antitumor phenotype was stimulated on macrophages. The ultimate anti-melanoma effect emerges from an association between the viability, migration and macrophagic phenotype modulation. These results display the remarkable antitumour effect of the xanthohumol-loaded PLGA nanoparticles and are the first advance towards the application of a nanoformulation to deliver xanthohumol to reduce adverse effects by currently employed chemotherapeutics.

Dados da publicação

ISSN/ISSNe:
1996-1944, 1996-1944

Materials  MDPI AG

Tipo:
Article
Páginas:
6421-
Link para outro recurso:
www.scopus.com

Citações Recebidas na Web of Science: 4

Citações Recebidas na Scopus: 13

Documentos

  • Não há documentos

Métricas

Filiações mostrar / ocultar

Keywords

  • melanoma; xanthohumol; PLGA nanoparticle; macrophage; antitumour; antiproliferative; drug delivery; cancer

Financiamento

Proyectos asociados

Effects of Xanthohumol on Metabolic Syndrome Progression (XAN4Health) - NCT03561116

Investigador Principal: Raquel Ângela Silva Soares Lino

Ensaio Clínico Académico (XAN4Health) . TA XAN . 2019

SARS-CoV-2 e Angiogénese: uma ligação por explicar

Investigador Principal: Raquel Ângela Silva Soares Lino

Estudo Clínico Académico . 2021

Citar a publicação

Partilhar a publicação